CytomX Therapeutics (NASDAQ:CTMX) reported its full-year 2025 financial results and a strategic business update on March 16, 2026, highlighting the continued evolution of its Probody® platform.
The South San Francisco-based biotechnology firm announced positive Phase 1 data for Varseta-M, a masked antibody-drug conjugate (ADC), in patients with advanced colorectal cancer (CRC).
The results demonstrated a manageable safety profile and promising anti-tumor activity in a heavily pre-treated patient population.
Building on this momentum, CytomX has initiated a new clinical cohort evaluating Varseta-M in combination with bevacizumab, aiming to enhance treatment efficacy in late-stage CRC.
The company is currently in discussions with the FDA and targets mid-2026 for alignment on the design of a registrational trial.
Success in this regulatory milestone would transition CytomX into a late-stage clinical organization.
Additionally, the company expects to release combination data for CX-801, its interferon alpha-2b Probody cytokine, by the end of 2026.
Financially, CytomX reported 2025 revenue of $76.2 million, a decrease from the $138.1 million recognized in 2024.